ERBB2 and cancer: Liposomal drug delivery targeting HER2 has been well studied, and immunoliposomes displaying anti-HER2 antibodies such as trastuzumab exhibit greater anticancer activity than non-targeting liposomes by specifically targeting HER2-overexpressing cancer cells [9]–[12].